AOD-9604

🔹 What is AOD-9604?

Class: Synthetic peptide fragment—AOD-9604 is a modified C-terminal fragment of human growth hormone (hGH), specifically the 176–191 amino acid sequence. Mechanism: Mimics the lipolytic (fat-burning) properties of growth hormone without significantly affecting blood sugar or growth pathways. Stimulates lipolysis, inhibits lipogenesis, and may improve triglyceride metabolism. It interacts with fat cells (adipocytes) to promote fat breakdown and reduce storage, particularly in visceral fat. Primary focus: Fat loss, metabolic regulation, body composition improvement, potential joint/tissue repair, and mitochondrial support. Ongoing research: Beyond fat loss, AOD-9604 has trials underway for osteoarthritis, hypercholesterolemia, and bone/cartilage repair—reflecting its dual identity as both a metabolic fragment and a tissue-supportive peptide.

---

🔹 Oral Dosage (least common) Range studied/used in research: Oral bioavailability is low; most clinical data is from subcutaneous injection. Typical protocol: Oral forms exist as capsules or sprays (sublingual), but precise dosing remains speculative and under-documented. Notes: Injectable or subcutaneous routes are vastly preferred for consistent systemic and fat-cell targeting. Oral/spray data is anecdotal.

---

🔹 Sublingual Troche Dosage Range: AOD-9604 500 mcg troche. Typical protocol: Dissolve 1 troche daily under the tongue for 20 days. Notes: Offered by some compounding pharmacies as a convenient alternative to daily subcutaneous injection.

---

🔹 Injectable / Subcutaneous Dosage (most common) Range: Research and anecdotal reports commonly use 150–300 µg per day subcutaneously. Higher doses have been trialed in clinical studies for obesity and metabolic endpoints. Frequency: Typically once daily, sometimes split into two smaller doses (AM + PM) for sustained effect. Rationale: Peptide fragment is stable and active at low microgram doses; subcutaneous injection ensures predictable systemic absorption. Clinic protocol examples: Advitam dosing runs 300 mcg SubQ, 20 days on / 10 days off; other protocols use 250 mcg BID for fat loss. AOD-9604 is also available in oral and topical forms in addition to SubQ. Length of treatment varies widely—from 6 weeks to 3 months, up to 6 months.

---

🔹 Intra-Articular (Joint) Dosage Combination: AOD-9604 combined with hyaluronic acid (AOD/HA), injected directly into the joint rather than subcutaneously—a distinct application from the fat-loss use case above, aimed at cartilage regrowth and increasing intra-articular IGF-1/bioavailability at the joint itself. Range: 0.5–1.0 ml intra-articularly, single or split dose, depending on the injured joint or injection site. Arthritis-specific protocol: 0.5 ml once weekly for 5 doses, followed by 0.5 ml once monthly for 3 doses (8 doses total). Notes: This is a joint-health application distinct from the systemic/subcutaneous fat-loss protocols above and should be administered by a qualified injector familiar with intra-articular technique.

---

🔹 Cycle Length Common cycle length: Clinical trials and user reports often run 8–12 weeks. Off-cycle: Breaks of 2–4 weeks are occasionally used to evaluate efficacy or prevent adaptation, though receptor desensitization is not well-studied. Note: Limited research; durations are extrapolated from similar hGH fragment studies.

---

🔹 Optimal Dosing Window Oral: Insufficient data; not recommended for reliable systemic effect. Injectable / Subcutaneous: Morning dosing is often preferred to align with natural circadian GH rhythm, potentially supporting lipid metabolism during the active day. Avoid late evening dosing to reduce risk of interference with sleep hormone cycles. Reddit | Biolab Shop

Clinical pearl: AOD-9604 is not recommended as a stand-alone weight-loss treatment—clinicians have not found it to yield consistent results for weight loss on its own. It works best combined with a GLP-1 agonist or other peptides, particularly for patients with 30+ lbs to lose or those not getting expected results from a GLP-1 alone. It’s also a good adjunct for patients who aren’t good candidates for GHRPs, since AOD-9604 (despite being an hGH fragment) does not promote growth hormone release. Run it for a minimum of 3 months in a row—one month alone typically does not show results. AOD-9604 is GRAS (generally recognized as safe) in foods under conditions of intended use, and no allergic reactions have been reported.

---

✅ Educational Integration Example (oral) Not recommended due to low absorption and lack of robust data. ✅ Educational Integration Example (injectable) Example protocol: 200 µg subcutaneous injection once daily at 8 AM for 10 weeks, followed by a 3-week break. Pair with: Balanced nutrition (higher protein, moderate carbs/fats), resistance training, and cardiovascular activity to maximize fat-loss outcomes.

---

🔹 Stacking Strategy (Educational) Since AOD-9604 primarily targets lipolysis and metabolism, supporting systemic energy balance and tissue health enhances outcomes: 🔸 Metabolic & Fat Loss Support

• CJC-1295/Ipamorelin: May support fat loss and tissue regeneration through GH axis modulation.
• L-Carnitine / L-Carnitine blends: Enhance mitochondrial fat transport and utilization.
• Cardarine (GW-501516, research use only): May complement fat oxidation pathways.

🔸 Recovery & Tissue Support

• BPC-157 or TB-500: Aid connective tissue repair, helpful if exercise intensity is high.
• Collagen peptides: Joint and tendon support alongside fat-loss protocol.

🔸 Longevity / Metabolic Health

• NAD⁺ precursors (NMN/NR): Support mitochondrial function and systemic energy.
• Omega-3 fatty acids: Enhance metabolic efficiency and reduce inflammation.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.